Şunu aradınız:: prednimustine (İngilizce - Almanca)

prednimustine
prednimustin

[0169] examples of cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosylate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methylpyridine) platinum, benzylguanine, glufosfamide, gpx100, (trans,trans,trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(ii)]bis[diamine(chloro)platinum (ii)] tetrachloride, diarizidinyl-spermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3′-deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, men10755 and 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulfonyldaunorubicin (see wo 00/50032).
zu den zytotoxika zählen zum beispiel tirapazimin, sertenef, cachectin, ifosfamid, tasonermin, lonidamin, carboplatin, altretamin, prednimustin, dibromdulcit, ranimustin, fotemustin, nedaplatin, oxaliplatin, temozolomid, heptaplatin, estramustin, improsulfan-tosylat, trofosfamid, nimustin, dibrospidium-chlorid, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamid, cis-amindichlor(2-methylpyridin)platin, benzylguanin, glufosfamid, gpx100, (trans,trans,trans)-bis-mu-(hexan-1,6-diamin)-mu-[diaminplatin(ii)]bis[diamin(chlor)platin(ii)]-tetrachlorid, diarizidinylspermin, arsentrioxid, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthin, zorubicin, idarubicin, daunorubicin, bisantren, mitoxantron, pirarubicin, pinafid, valrubicin, amrubicin, antineoplaston, 3'-desamino-3'-morpholino-13-desoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafid, men10755 und 4-desmethoxy-3-desamino-3-aziridinyl-4-methylsulfonyldaunorubicin (siehe wo 00/50032), was jedoch keine einschränkung darstellen soll.